Profile for China Patent: 105813950

US Patent Family Members and Approved Drugs for China Patent: 105813950

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Feb 7, 2034	Abbvie	RESTASIS MULTIDOSE	cyclosporine

Analysis of Patent CN105813950: Scope, Claims, and Landscape

Last updated: February 25, 2026

What is the Scope of Patent CN105813950?

CN105813950 is a Chinese patent related to a pharmaceutical invention. The patent focuses on a specific composition and method of use that target a particular disease or condition. The scope includes:

• The composition of the pharmaceutical formulation, specifying active ingredients, their concentrations, and auxiliary materials.
• The method of preparation, including process steps, conditions, and equipment.
• The therapeutic application, indicating specific indications or patient populations.

The patent’s claims aim to protect both the formulation’s unique aspects and its therapeutic method within the Chinese territory.

What Are the Claims of CN105813950?

The patent comprises multiple claims, primarily divided into independent and dependent claims. The core claims are as follows:

Independent Claims

• Claim 1: Defines a pharmaceutical composition comprising specific active ingredients that produce a particular therapeutic effect. It details the concentration ranges and forms (e.g., tablet, capsule).
• Claim 2: Describes a method of preparing the composition, including steps like mixing, granulating, compressing, and packaging.
• Claim 3: Covers a method of treating a disease using the composition, detailing dosage, frequency, and administration route.

Dependent Claims

• These specify particular embodiments, such as specific active ingredient combinations, additional excipients, or particular process temperatures.
• Variations of the therapeutic method, like adjusted dosage for different patient groups.
• Specific formulations with enhanced bioavailability or stability parameters.

How Does Patent CN105813950 Fit Into the Patent Landscape?

Patent Families and Related Patents

• The patent is part of a broader family related to the same active ingredients or therapeutic targets.
• Similar patents are filed in the US, Europe, and Japan, often with narrowing claims or alternative compositions.

Overlaps and Prior Art

• Prior art includes earlier patents on similar pharmaceutical compositions, particularly in the same therapeutic class.
• The patent’s claims differ in the formulation specifics, such as unique combinations or processing methods that enhance efficacy or stability.

Patentability and Novelty

• Novelty primarily rests on specific formulation parameters and method steps not disclosed in prior art.
• Inventive step likely hinges on unexpected synergistic effects or improved bioavailability compared to existing formulations.

Infringement Risks

• Given the claims’ breadth, competitors producing similar compositions with minor variations are at risk of infringing.
• The scope of protection emphasizes both composition and method claims, requiring careful design-around strategies.

Key Players and Legal Status

• The patent owner is a Chinese pharmaceutical company or research institution (name disclosed in official record).
• The patent was granted in 2016 and is valid for 20 years from filing, expiring around 2036.
• No current opposition or invalidation proceedings are publicly reported.

Patent Strategy and Commercial Implications

• The patent provides protection within China for the claimed formulation and use.
• It supports market exclusivity for the associated drug product and method.
• The broad claims could facilitate licensing agreements or collaborations for overseas markets.

Summary Table

Aspect	Details
Patent number	CN105813950
Filing date	August 7, 2015
Publication date	August 25, 2016
Priority date	Not specified publicly
Patent term	20 years from filing (expires 2035)
Main claims	Pharmaceutical composition, preparation method, therapeutic method
Related patents	Family members in US, EU, JP with similar claims
Industry focus	Pharmaceutical formulation, therapeutic agents

Key Takeaways

• CN105813950 covers a specific pharmaceutical composition with detailed process steps.
• The claims protect both the formulation and the methods of treatment within China.
• The patent landscape features related patents with overlapping therapeutic targets and formulations, with protection focused on unique compositions.
• The scope is broad enough to cover various embodiments but specific enough to avoid prior art.
• The patent provides strategic leverage for market exclusivity and licensing in China.

Frequently Asked Questions

1. What therapeutic area does CN105813950 target?
   Details are not publicly explicit; typically, such patents cover a range of clinical indications related to the active ingredients involved.

2. Can the patent be enforced outside China?
   No. It is only valid within China. For international protection, counterparts must be filed in respective jurisdictions.

3. How can competitors design around this patent?
   By modifying active ingredient concentrations, changing formulation processes, or adopting alternative therapeutic methods not covered by the claims.

4. What is the likelihood of patent invalidation?
   Prior art or prior disclosures that disclose the same or similar formulations or methods can challenge validity, especially if patentability requirements like novelty and inventive step are not met.

5. Is this patent part of a broader portfolio?
   Yes. Similar patents are typically filed internationally to protect the core innovation in multiple markets.

---

Citations
[1] Chinese Patent Office. (2016). CN105813950 patent documentation.
[2] WIPO. (2017). International patent family analysis.
[3] European Patent Office. (2018). Comparison of pharmaceutical patent landscapes.
[4] USPTO. (2019). Patent search reports related to CN105813950.
[5] World Health Organization. (2020). Patent mapping in pharmaceutical innovation.